The main findings of this study are as follows: (1) In both the 3xTG AD model and the APP/PS1/Tau AD model, the signal enhancement after injection of our developed contrast agent was observed from 16 weeks of age, confirming the potential for early diagnosis of AD. The gene discussed is MAPT; the disease is Alzheimer disease.